EGFR and neoplasm: The resulting CD9-CD38/αCD3-αEGFR exosomes (Exos) were next incubated with the synthesized 2′-Cl-araNAD+-BP conjugate to generate BP-αCD3-αEGFR-ARC Exos that are expected to recruit and activate cytotoxic T cells toward elimination of bone-metastasized EGFR+ tumor cells via surface-anchored αCD3 and αEGFR antibodies and BP molecules (Fig. 5A, and Supplementary Fig. 7a).